Liver Diseases

• FDA approval · 2018-07-26
  FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  The FDA approved a supplemental application for EOVIST (gadoxetate disodium) to expand/update its labeling for MRI imaging of focal liver le…

• FDA approval · 2016-03-31
  FDA Approved: LUMASON — Supplemental Application (BRACCO DIAGNOSTICS INC)

  FDA approves a supplemental application for Lumason (sulfur hexafluoride) from Bracco Diagnostics to expand the approved indications for ult…

• FDA approval · 2013-10-16
  FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  The FDA has approved Bayer's supplemental application for Eovist (gadoxetate disodium), updating its labeling to expand its use as an MRI co…

• FDA approval · 2009-11-13
  FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

  FDA approved a supplemental application for EOVIST (gadoxetate disodium) from Bayer HealthCare Pharmaceuticals Inc.

• FDA approval · 2007-09-19
  FDA Approved: CHOLETEC — Supplemental Application (Bracco Diagnostics Inc)

  FDA approved a supplemental application for CHOLETEC (Mebrofenin) submitted by Bracco Diagnostics Inc. CHOLETEC is a radiopharmaceutical age…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.